CYCC up big today on Shkreli rumor. And the structure of CYCC much different than KBIO in terms of outstanding shares and shorts and market cap. So, i would expect this to continue in other small bio stocks with a pipeline. Who knows where rumor will hit next time but its clear that Shkreli is not going to do anything to stop ongoing speculations. Below is a comment on his twitter feed.
Twitter people. Don't pitch me stocks. I have a team of 20+ professionals looking to acquire drugs and drug companies. I listen to them
Yes, vaso is the Lucy to the Charlie Browns here(the shareholders). Will Charlie get to kick that football this time?
Reseller, you appear as you want to be considered the expert here, yet nothing you have said since first posting here has ever come true. You are a joke and the perfect spokesperson of the times; just say something loud and often, and it will be so. Good luck with that.
I have been here many years.(like smalls) I made 6 figures+ accummulating 100's of thousands of shares at a nickel and selling into the ge agreement years ago. Back then, board was dead and stock was flatline. It was frustrating. to say the least. IMHO, we are about to see another huge gain for those who have been patiently accumulating under 20 cents.
Happy T day
Well, if you say it, it must be true..........................
Really dont care what or how they make money here, as long as they do. Best Q of the year coming up, and stock sits under 20 cents. Got to be a buyer here.........IMHO
Results may be known. Maybe reason for insider buying? Time to buy, stock has consolidated enough.
David Grant U.S. Air Force Medical Center:
Primary Outcome Measures: •Change in delayed onset muscle soreness over time. [ Time Frame: At 3, 6, 9, 12, 15, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 Hours ] [ Designated as safety issue: No ]
Likert pain surveys
Secondary Outcome Measures: •Pain tolerance [ Time Frame: Baseline, 24 hours, 2 days 3 days 4 days 33 days ] [ Designated as safety issue: No ]
Pain tolerance measured by mmHg pressure required to elicit a delayed-onset muscle pain response.
•Bio-markers for muscle inflammation [ Time Frame: Baseline, 24 hours, 2 days 3 days 4 days 33 days ] [ Designated as safety issue: No ]
Bio-markers for muscle inflammation: C-reactive protein, creatine phosphokinase, and white blood cell count
Estimated Enrollment: 20
Study Start Date: April 2014
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure
Your reply was on target and pointed out the obvious, at least to the many long timers here. Of course our outstanding shares is much different and there is no way for anyone to really quantify what the short position is here. Enough to know that it must be a large one.
My point was that shorts, any short, has to be looking over his shoulder now that any small bio with decent drugs in the pipeline can be a career destroyer once an investor takes a stake. These underfunded bio's used to be a layup for the shorts................no longer so............
hey mia, your posts have been a little postive lately. But then you revert back to name calling. I dont know why you are so hostile all the time. Is your wife not giving you any?( Who could blame him) No wonder sno broke up with you.
Of course the two companies are different. But the possiblity of some large investor taking a stake remains. Its just one of the many positive outcomes we may see here in the near future. I talk my book all the time, and its all fact based. I have no clue what your motivation for being here is.
This stock was 40 cents, just like rgrx, a week ago. And now, 36 dollars. Unreal.
This is what a massive short squeeze looks like. And it may become the new example of how aggressive big investors(ackmann) play. Just look for a small bio with a very small float, and large short ratio. Ideally company would have a couple drugs in the pipeline that, once the stake has been made public, investor could hype. These drugs in the pipeline may have been underappreciated and underfunded but still have a story and new life, now that investor has invested. Kbio has shown it can be done. Shorts have and are being crushed now that KBIO will become more than just a going concern.
At the very least shorts will be very alert to the possiblity of this happening again. Losses are so massive that shorts in kbio will forced be to cover other positions, and might even go BK.
As far as KBIO's pipeline, rgrx's is better and has a better chance of reaching approval in a bigger market. What would happen if large investor took a nice chunk of rgrx? The heart indication alone could provide enough sizzle to sink the short here. Sure, its a wet dream for longs. but a real nightmare for short. Just dont see the risk/reward remaining short here.
Sno, what is your problem? The stock started the year around 13 cents and had its biggest one day volume event in late feb at 1.3 million shares at around 20 cents. Two other biggest volume days were done well under 40 cents.
What you dont understant about the chart here could fill a book, Look at the tight trading range consolidating prices from july till now..35 to 50 cents. And most stock done in the past months right around here. If there has been any tax sellers from the highs, they have been part of the orderly supply we have seen. Add to that the 200 dma is at .39. This is not a chart that will show big tax selling into the end of the year.
RGRX has a much diffferent look to it than the last many years. I am sorry you insist on trying to slant everything in such a negative fashion. You will need to go back to bashing JJ, cause you tax selling "hope" scare tactic is way off base and factual incorrect.
Mia, your false bravado on an internet message board is laughable. And your constant references to homosexuality should worry that wife of yours: whatever his name is.
If you are a long(and how would i know this based on your worthless posts), why dont you contribute something useful about rgrx. The donk and sno, I may not agree with them, but they try and add to the investment thesis here.
"I have read almost every post here for ten plus years"
Why would a person take the time over the last 10 years to read every post on a investment message board he has no investment in? It boggles the sane mind to think that anyone would be so devoid of activities in their daily life that would allow them to do this.
Mia, the comments you make are a function(dysfunction) of the anonymity of the internet. In the real world, the 1/2 of man that you must be would never has the set of B's to say anything to any of the posters here.
You give new meaning to that waste that mankind has become; and in a world where that religious cult is killing innocents, that is saying something.
" like trading in these markets." Not really. I started buying rgrx(rgn) when it was listed on the Naz. Its been a long time and i agree i hope whatever deal materializes really benefits all shareholders.
And pinning a stock for a long period of time is not unique to the OTC. Its done(dont know how) on many listed stocks before big moves.
Unreal. They have no drugs just some p2's. What a scam some of these markets are. Whatever. Maybe Fink should call that lowlife Shkreli(remember he bought an old drug and marked it up 1000%; he brought attention on drug pricing) and have him make a purchase of rgrx. Can you imagine how high we would go with our short positiion.
Drug developer KaloBios Pharmaceuticals Inc's shares rose five-fold in extended trading after Turing Pharmaceuticals Inc's Chief Executive Martin Shkreli bought 1.2 million shares of KaloBios.
It looked like we might break out near the end of the day as real buyers took offer up to .43. Decent size hit that number and then 10k sells to take stock back to .41. Its just amazing how pinned this stock is. No real long, who you would assume would want the highest price possible, would sell a lousy 10k shares below the then bid and halt rally. You would let stock run and then put some out on the offer.
I have seen this type of action before buyouts. Who knows but for certain player is very determined to keep stock here for some reason. All i can say is "buy'em if you can................news is coming.
Very unusual here. A buyer of 2500 may 13 calls at prices from 2.05 to 2.15. The market on these when bought was 1.05 x 2.05. Huge spread and buyer very motivated.
Longer terms, stock must be well over 15 to make money. This looks like a play on amgen buyout. Very bullish stuff
I say again and the stock price backs me up; buyers do not trust Ma. They feel he is an incompetent. If he were to resign or be fired, stock would rally.
Reseller, you are a vaso fool who communicates a factless, bullish bias.
LOL. You are a funny guy. Vaso gets this worthless award every year, and every year stock has gone lower.
Maybe this is the new shareholder disclosure castle is talking about. Its a real insult to shareholders that Ma even bothers with this nonsense.
Ma is no longer needed. Castle should fire him
On 6 drops daily, total corneal staining was statistically significant. The dry eye trial missed on only 1 subgroup(inferior) with 2 drops. Ongoing trial uses 4 drops and some higher dosing. What are the odds that average total will be significant? Very, very good.....IMHO...this will dominate the dry eye market and shires drug.
In the trial, nine patients with severe dry eye (18 eyes) were treated with RGN-259 or vehicle control six times daily over a period of 28 days. They were evaluated upon entering the study after a two-week washout period, at weekly intervals during the treatment phase, at the end of the 28-day treatment period, and at a follow-up visit 28 days after treatment. Statistically significant differences in sign and symptom assessments, such as ocular discomfort and corneal fluorescein staining, were seen at various time points throughout the study. Of particular note were the differences between RGN-259 and vehicle control 28 days post-treatment, or the follow-up period. The RGN-259-treated group had a 35.1% reduction of ocular discomfort compared to vehicle control (p = 0.0141), and a 59.1% reduction of total corneal fluorescein staining compared to vehicle control (p = 0.0108) at 28 days after treatment showing that the repair was sustained long after treatment cessation